Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer

Abstract Background Esophageal pleural fistula (EPF) is a rare but fatal complication associated with bevacizumab use; however, cases reports of EPF caused by bevacizumab have not been previously published. Case presentation A 66-year-old male patient diagnosed with stage IV lung adenocarcinoma on A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ting Wang, Asmitananda Thakur, Baoqing Chen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Bevacizumab Lung cancer Esophageal pleural fistula Case report Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/fb6bc0fc80fa4d6f9d1ba67702b324f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb6bc0fc80fa4d6f9d1ba67702b324f1
record_format	dspace
spelling	oai:doaj.org-article:fb6bc0fc80fa4d6f9d1ba67702b324f12021-11-28T12:36:29ZBevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer10.1186/s12890-021-01750-w1471-2466https://doaj.org/article/fb6bc0fc80fa4d6f9d1ba67702b324f12021-11-01T00:00:00Zhttps://doi.org/10.1186/s12890-021-01750-whttps://doaj.org/toc/1471-2466Abstract Background Esophageal pleural fistula (EPF) is a rare but fatal complication associated with bevacizumab use; however, cases reports of EPF caused by bevacizumab have not been previously published. Case presentation A 66-year-old male patient diagnosed with stage IV lung adenocarcinoma on April 24, 2020 received 6 cycles of platinum-containing dual chemotherapy combined with bevacizumab followed by three cycles of bevacizumab monotherapy. Five days before admission, he experienced chest tightness, dyspnea, and right chest pain. Bed-side X-ray examination revealed a massive right hydrothorax, and food was found in the extracted pleural effusion. EPF was further confirmed by upper gastrointestinal radiography after oral administration of iohexol. The patient underwent jejunostomy as the distal esophagus could not be identified on gastroscopy, and eventually died of septic shock on January 16, 2021. Conclusions It is necessary to pay attention to EPF during bevacizumab use in patients with or without risk factors.Ting WangAsmitananda ThakurBaoqing ChenBMCarticleBevacizumabLung cancerEsophageal pleural fistulaCase reportDiseases of the respiratory systemRC705-779ENBMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bevacizumab Lung cancer Esophageal pleural fistula Case report Diseases of the respiratory system RC705-779
spellingShingle	Bevacizumab Lung cancer Esophageal pleural fistula Case report Diseases of the respiratory system RC705-779 Ting Wang Asmitananda Thakur Baoqing Chen Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
description	Abstract Background Esophageal pleural fistula (EPF) is a rare but fatal complication associated with bevacizumab use; however, cases reports of EPF caused by bevacizumab have not been previously published. Case presentation A 66-year-old male patient diagnosed with stage IV lung adenocarcinoma on April 24, 2020 received 6 cycles of platinum-containing dual chemotherapy combined with bevacizumab followed by three cycles of bevacizumab monotherapy. Five days before admission, he experienced chest tightness, dyspnea, and right chest pain. Bed-side X-ray examination revealed a massive right hydrothorax, and food was found in the extracted pleural effusion. EPF was further confirmed by upper gastrointestinal radiography after oral administration of iohexol. The patient underwent jejunostomy as the distal esophagus could not be identified on gastroscopy, and eventually died of septic shock on January 16, 2021. Conclusions It is necessary to pay attention to EPF during bevacizumab use in patients with or without risk factors.
format	article
author	Ting Wang Asmitananda Thakur Baoqing Chen
author_facet	Ting Wang Asmitananda Thakur Baoqing Chen
author_sort	Ting Wang
title	Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
title_short	Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
title_full	Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
title_fullStr	Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
title_full_unstemmed	Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
title_sort	bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer
publisher	BMC
publishDate	2021
url	https://doaj.org/article/fb6bc0fc80fa4d6f9d1ba67702b324f1
work_keys_str_mv	AT tingwang bevacizumabinducedesophagealpleuralfistuladuringmaintenancetherapywithoutradiationinlungcancer AT asmitanandathakur bevacizumabinducedesophagealpleuralfistuladuringmaintenancetherapywithoutradiationinlungcancer AT baoqingchen bevacizumabinducedesophagealpleuralfistuladuringmaintenancetherapywithoutradiationinlungcancer
_version_	1718407931543683072

Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer

Ejemplares similares